Skip to main content
Top
Published in: Gastric Cancer 1/2023

12-09-2022 | Helicobacter Pylori | Original Article

Transcriptome analysis reveals the essential role of NK2 homeobox 1/thyroid transcription factor 1 (NKX2-1/TTF-1) in gastric adenocarcinoma of fundic-gland type

Authors: Kazushi Fukagawa, Yu Takahashi, Nobutake Yamamichi, Natsuko Kageyama-Yahara, Yoshiki Sakaguchi, Miho Obata, Rina Cho, Nobuyuki Sakuma, Sayaka Nagao, Yuko Miura, Naoki Tamura, Daisuke Ohki, Hiroya Mizutani, Seiichi Yakabi, Chihiro Minatsuki, Keiko Niimi, Yosuke Tsuji, Mitsue Yamamichi, Narumi Shigi, Shuta Tomida, Hiroyuki Abe, Tetsuo Ushiku, Kazuhiko Koike, Mitsuhiro Fujishiro

Published in: Gastric Cancer | Issue 1/2023

Login to get access

Abstract

Background

Gastric adenocarcinoma of fundic-gland type (GA-FG) is a gastric malignancy with little relation to Helicobacter pylori. Clinical characteristics of GA-FG have been established, but molecular mechanisms leading to tumorigenesis have not yet been elucidated.

Methods

We subjected three GA-FG tumors-normal mucosa pairs to microarray analysis. Network analysis was performed for the top 30 up-regulated gene transcripts, followed by immunohistochemical staining to confirm the gene expression analysis results. AGS and NUGC4 cells were transfected with the gene-encoding NK2 homeobox 1/thyroid transcription factor 1 (NKX2-1/TTF-1) to evaluate transcriptional changes in its target genes.

Results

Comprehensive gene expression analysis identified 1410 up-regulated and 1395 down-regulated gene probes with ≥ two-fold difference in expression. Among the top 30 up-regulated genes in GA-FG, we identified transcription factor NKX2-1/TTF-1, a master regulator of lung/thyroid differentiation, together with surfactant protein B (SFTPB), SFTPC, and secretoglobin family 3A member 2(SCGB3A2), which are regulated by NKX2-1/TTF-1. Immunohistochemical analysis of 16 GA-FG specimens demonstrated significantly higher NKX2-1/TTF-1 and SFTPB levels, as compared to that in adjacent normal mucosa (P < 0.05), while SCGB3A2 levels did not differ (P = 0.341). Transduction of NKX2-1/TTF-1 into AGS and NUGC4 cells induced transactivation of SFTPB and SFTPC, indicating that NKX2-1/TTF-1 can function as normally in gastric cells as it can in the lung cells.

Conclusions

Our first transcriptome analysis of GA-FG indicates significant expression of NKX2-1/TTF1 in GA-FG. Immunohistochemistry and cell biology show ectopic expression and normal transactivation ability of NKX2-1/TTF-1, suggesting that it plays an essential role in GA-FG development.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRef Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRef
2.
go back to reference Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens–Part B: biological agents. Lancet Oncol. 2009;10(4):321–2.CrossRef Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens–Part B: biological agents. Lancet Oncol. 2009;10(4):321–2.CrossRef
3.
go back to reference Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7–14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1–241. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7–14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1–241.
4.
go back to reference Inoue M. Changing epidemiology of Helicobacter pylori in Japan. Gastric Cancer. 2017;20(Suppl 1):3–7.CrossRef Inoue M. Changing epidemiology of Helicobacter pylori in Japan. Gastric Cancer. 2017;20(Suppl 1):3–7.CrossRef
5.
go back to reference Wang C, Nishiyama T, Kikuchi S, Inoue M, Sawada N, Tsugane S, et al. Changing trends in the prevalence of H pylori infection in Japan (1908–2003): a systematic review and meta-regression analysis of 170,752 individuals. Sci Rep. 2017;7(1):15491.CrossRef Wang C, Nishiyama T, Kikuchi S, Inoue M, Sawada N, Tsugane S, et al. Changing trends in the prevalence of H pylori infection in Japan (1908–2003): a systematic review and meta-regression analysis of 170,752 individuals. Sci Rep. 2017;7(1):15491.CrossRef
6.
go back to reference Tsukamoto T, Yokoi T, Maruta S, Kitamura M, Yamamoto T, Ban H, et al. Gastric adenocarcinoma with chief cell differentiation. Pathol Int. 2007;57(8):517–22.CrossRef Tsukamoto T, Yokoi T, Maruta S, Kitamura M, Yamamoto T, Ban H, et al. Gastric adenocarcinoma with chief cell differentiation. Pathol Int. 2007;57(8):517–22.CrossRef
8.
go back to reference Park ES, Kim YE, Park CK, Yao T, Kushima R, Kim KM. Gastric adenocarcinoma of fundic gland type: report of three cases. Korean J Pathol. 2012;46(3):287–91.CrossRef Park ES, Kim YE, Park CK, Yao T, Kushima R, Kim KM. Gastric adenocarcinoma of fundic gland type: report of three cases. Korean J Pathol. 2012;46(3):287–91.CrossRef
9.
go back to reference Hidaka Y, Mitomi H, Saito T, Takahashi M, Lee SY, Matsumoto K, et al. Alteration in the Wnt/β-catenin signaling pathway in gastric neoplasias of fundic gland (chief cell predominant) type. Hum Pathol. 2013;44(11):2438–48.CrossRef Hidaka Y, Mitomi H, Saito T, Takahashi M, Lee SY, Matsumoto K, et al. Alteration in the Wnt/β-catenin signaling pathway in gastric neoplasias of fundic gland (chief cell predominant) type. Hum Pathol. 2013;44(11):2438–48.CrossRef
10.
go back to reference Miyazawa M, Matsuda M, Yano M, Hara Y, Arihara F, Horita Y, et al. Gastric adenocarcinoma of fundic gland type: Five cases treated with endoscopic resection. World J Gastroenterol. 2015;21(26):8208–14.CrossRef Miyazawa M, Matsuda M, Yano M, Hara Y, Arihara F, Horita Y, et al. Gastric adenocarcinoma of fundic gland type: Five cases treated with endoscopic resection. World J Gastroenterol. 2015;21(26):8208–14.CrossRef
11.
go back to reference Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345(11):784–9.CrossRef Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345(11):784–9.CrossRef
12.
go back to reference Benedict MA, Lauwers GY, Jain D. Gastric Adenocarcinoma of the fundic gland type: update and literature review. Am J Clin Pathol. 2018;149(6):461–73.CrossRef Benedict MA, Lauwers GY, Jain D. Gastric Adenocarcinoma of the fundic gland type: update and literature review. Am J Clin Pathol. 2018;149(6):461–73.CrossRef
13.
go back to reference Chiba T, Kato K, Masuda T, Ohara S, Iwama N, Shimada T, et al. Clinicopathological features of gastric adenocarcinoma of the fundic gland (chief cell predominant type) by retrospective and prospective analyses of endoscopic findings. Dig Endosc. 2016;28(7):722–30.CrossRef Chiba T, Kato K, Masuda T, Ohara S, Iwama N, Shimada T, et al. Clinicopathological features of gastric adenocarcinoma of the fundic gland (chief cell predominant type) by retrospective and prospective analyses of endoscopic findings. Dig Endosc. 2016;28(7):722–30.CrossRef
14.
go back to reference Ueyama H, Yao T, Nakashima Y, Hirakawa K, Oshiro Y, Hirahashi M, et al. Gastric adenocarcinoma of fundic gland type (chief cell predominant type): proposal for a new entity of gastric adenocarcinoma. Am J Surg Pathol. 2010;34(5):609–19.CrossRef Ueyama H, Yao T, Nakashima Y, Hirakawa K, Oshiro Y, Hirahashi M, et al. Gastric adenocarcinoma of fundic gland type (chief cell predominant type): proposal for a new entity of gastric adenocarcinoma. Am J Surg Pathol. 2010;34(5):609–19.CrossRef
15.
go back to reference Kushima R, Sekine S, Matsubara A, Taniguchi H, Ikegami M, Tsuda H. Gastric adenocarcinoma of the fundic gland type shares common genetic and phenotypic features with pyloric gland adenoma. Pathol Int. 2013;63(6):318–25.CrossRef Kushima R, Sekine S, Matsubara A, Taniguchi H, Ikegami M, Tsuda H. Gastric adenocarcinoma of the fundic gland type shares common genetic and phenotypic features with pyloric gland adenoma. Pathol Int. 2013;63(6):318–25.CrossRef
16.
go back to reference Tohda G, Osawa T, Asada Y, Dochin M, Terahata S. Gastric adenocarcinoma of fundic gland type: Endoscopic and clinicopathological features. World J Gastrointest Endosc. 2016;8(4):244–51.CrossRef Tohda G, Osawa T, Asada Y, Dochin M, Terahata S. Gastric adenocarcinoma of fundic gland type: Endoscopic and clinicopathological features. World J Gastrointest Endosc. 2016;8(4):244–51.CrossRef
17.
go back to reference Nomura R, Saito T, Mitomi H, Hidaka Y, Lee SY, Watanabe S, et al. GNAS mutation as an alternative mechanism of activation of the Wnt/β-catenin signaling pathway in gastric adenocarcinoma of the fundic gland type. Hum Pathol. 2014;45(12):2488–96.CrossRef Nomura R, Saito T, Mitomi H, Hidaka Y, Lee SY, Watanabe S, et al. GNAS mutation as an alternative mechanism of activation of the Wnt/β-catenin signaling pathway in gastric adenocarcinoma of the fundic gland type. Hum Pathol. 2014;45(12):2488–96.CrossRef
18.
go back to reference Ushiku T, Kunita A, Kuroda R, Shinozaki-Ushiku A, Yamazawa S, Tsuji Y, et al. Oxyntic gland neoplasm of the stomach: expanding the spectrum and proposal of terminology. Mod Pathol. 2020;33(2):206–16.CrossRef Ushiku T, Kunita A, Kuroda R, Shinozaki-Ushiku A, Yamazawa S, Tsuji Y, et al. Oxyntic gland neoplasm of the stomach: expanding the spectrum and proposal of terminology. Mod Pathol. 2020;33(2):206–16.CrossRef
19.
go back to reference Kawasaki K, Kurahara K, Oshiro Y, Matsumoto T. Depressed gastric adenocarcinoma of the fundic gland type. Intern Med. 2016;55(5):543–4.CrossRef Kawasaki K, Kurahara K, Oshiro Y, Matsumoto T. Depressed gastric adenocarcinoma of the fundic gland type. Intern Med. 2016;55(5):543–4.CrossRef
20.
go back to reference Sato Y, Fujino T, Kasagawa A, Morita R, Ozawa SI, Matsuo Y, et al. Twelve-year natural history of a gastric adenocarcinoma of fundic gland type. Clin J Gastroenterol. 2016;9(6):345–51.CrossRef Sato Y, Fujino T, Kasagawa A, Morita R, Ozawa SI, Matsuo Y, et al. Twelve-year natural history of a gastric adenocarcinoma of fundic gland type. Clin J Gastroenterol. 2016;9(6):345–51.CrossRef
21.
go back to reference Kato M, Uraoka T, Isobe Y, Abe K, Hirata T, Takada Y, et al. A case of gastric adenocarcinoma of fundic gland type resected by combination of laparoscopic and endoscopic approaches to neoplasia with non-exposure technique (CLEAN-NET). Clin J Gastroenterol. 2015;8(6):393–9.CrossRef Kato M, Uraoka T, Isobe Y, Abe K, Hirata T, Takada Y, et al. A case of gastric adenocarcinoma of fundic gland type resected by combination of laparoscopic and endoscopic approaches to neoplasia with non-exposure technique (CLEAN-NET). Clin J Gastroenterol. 2015;8(6):393–9.CrossRef
22.
go back to reference Li C, Wu X, Yang S, Yang X, Yao J, Zheng H. Gastric adenocarcinoma of the fundic gland type: clinicopathological features of eight patients treated with endoscopic submucosal dissection. Diagn Pathol. 2020;15(1):131.CrossRef Li C, Wu X, Yang S, Yang X, Yao J, Zheng H. Gastric adenocarcinoma of the fundic gland type: clinicopathological features of eight patients treated with endoscopic submucosal dissection. Diagn Pathol. 2020;15(1):131.CrossRef
23.
go back to reference Kurihara N, Kubota T, Otani Y, Ohgami M, Kumai K, Sugiura H, et al. Lymph node metastasis of early gastric cancer with submucosal invasion. Br J Surg. 1998;85(6):835–9.CrossRef Kurihara N, Kubota T, Otani Y, Ohgami M, Kumai K, Sugiura H, et al. Lymph node metastasis of early gastric cancer with submucosal invasion. Br J Surg. 1998;85(6):835–9.CrossRef
24.
go back to reference Abe T, Nagai T, Fukunaga J, Okawara H, Nakashima H, Syutou M, et al. Long-term follow-up of gastric adenocarcinoma with chief cell differentiation using upper gastrointestinal tract endoscopy. Intern Med. 2013;52(14):1585–8.CrossRef Abe T, Nagai T, Fukunaga J, Okawara H, Nakashima H, Syutou M, et al. Long-term follow-up of gastric adenocarcinoma with chief cell differentiation using upper gastrointestinal tract endoscopy. Intern Med. 2013;52(14):1585–8.CrossRef
25.
go back to reference Abraham SC, Nobukawa B, Giardiello FM, Hamilton SR, Wu TT. Sporadic fundic gland polyps: common gastric polyps arising through activating mutations in the beta-catenin gene. Am J Pathol. 2001;158(3):1005–10.CrossRef Abraham SC, Nobukawa B, Giardiello FM, Hamilton SR, Wu TT. Sporadic fundic gland polyps: common gastric polyps arising through activating mutations in the beta-catenin gene. Am J Pathol. 2001;158(3):1005–10.CrossRef
26.
go back to reference Sekine S, Shibata T, Yamauchi Y, Nakanishi Y, Shimoda T, Sakamoto M, et al. Beta-catenin mutations in sporadic fundic gland polyps. Virchows Arch. 2002;440(4):381–6.CrossRef Sekine S, Shibata T, Yamauchi Y, Nakanishi Y, Shimoda T, Sakamoto M, et al. Beta-catenin mutations in sporadic fundic gland polyps. Virchows Arch. 2002;440(4):381–6.CrossRef
27.
go back to reference Sakaguchi Y, Yamamichi N, Tomida S, Takeuchi C, Kageyama-Yahara N, Takahashi Y, et al. Identification of marker genes and pathways specific to precancerous duodenal adenomas and early stage adenocarcinomas. J Gastroenterol. 2019;54(2):131–40.CrossRef Sakaguchi Y, Yamamichi N, Tomida S, Takeuchi C, Kageyama-Yahara N, Takahashi Y, et al. Identification of marker genes and pathways specific to precancerous duodenal adenomas and early stage adenocarcinomas. J Gastroenterol. 2019;54(2):131–40.CrossRef
28.
go back to reference Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9(7):676–82.CrossRef Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9(7):676–82.CrossRef
29.
go back to reference Landini G, Martinelli G, Piccinini F. Colour deconvolution: stain unmixing in histological imaging. Bioinformatics. 2021;37(10):1485–7.CrossRef Landini G, Martinelli G, Piccinini F. Colour deconvolution: stain unmixing in histological imaging. Bioinformatics. 2021;37(10):1485–7.CrossRef
30.
go back to reference Griesing S, Kajino T, Tai MC, Liu Z, Nakatochi M, Shimada Y, et al. Thyroid transcription factor-1-regulated microRNA-532-5p targets KRAS and MKL2 oncogenes and induces apoptosis in lung adenocarcinoma cells. Cancer Sci. 2017;108(7):1394–404.CrossRef Griesing S, Kajino T, Tai MC, Liu Z, Nakatochi M, Shimada Y, et al. Thyroid transcription factor-1-regulated microRNA-532-5p targets KRAS and MKL2 oncogenes and induces apoptosis in lung adenocarcinoma cells. Cancer Sci. 2017;108(7):1394–404.CrossRef
31.
go back to reference Yamamichi N, Yamamichi-Nishina M, Mizutani T, Watanabe H, Minoguchi S, Kobayashi N, et al. The Brm gene suppressed at the post-transcriptional level in various human cell lines is inducible by transient HDAC inhibitor treatment, which exhibits antioncogenic potential. Oncogene. 2005;24(35):5471–81.CrossRef Yamamichi N, Yamamichi-Nishina M, Mizutani T, Watanabe H, Minoguchi S, Kobayashi N, et al. The Brm gene suppressed at the post-transcriptional level in various human cell lines is inducible by transient HDAC inhibitor treatment, which exhibits antioncogenic potential. Oncogene. 2005;24(35):5471–81.CrossRef
33.
go back to reference Lindskog C, Fagerberg L, Hallström B, Edlund K, Hellwig B, Rahnenführer J, et al. The lung-specific proteome defined by integration of transcriptomics and antibody-based profiling. FASEB J. 2014;28(12):5184–96.CrossRef Lindskog C, Fagerberg L, Hallström B, Edlund K, Hellwig B, Rahnenführer J, et al. The lung-specific proteome defined by integration of transcriptomics and antibody-based profiling. FASEB J. 2014;28(12):5184–96.CrossRef
34.
go back to reference Niimi T, Keck-Waggoner CL, Popescu NC, Zhou Y, Levitt RC, Kimura S. UGRP1, a uteroglobin/Clara cell secretory protein-related protein, is a novel lung-enriched downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor. Mol Endocrinol. 2001;5(11):2021–36.CrossRef Niimi T, Keck-Waggoner CL, Popescu NC, Zhou Y, Levitt RC, Kimura S. UGRP1, a uteroglobin/Clara cell secretory protein-related protein, is a novel lung-enriched downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor. Mol Endocrinol. 2001;5(11):2021–36.CrossRef
35.
go back to reference Kim SK, Seok H, Park HJ, Han K, Kang SW, Ban JY, et al. Association between Secretoglobin family 3A member 2 (SCGB3A2) gene polymorphisms and asthma in a Korean Population. Med Sci Monit. 2017;23:1880–5.CrossRef Kim SK, Seok H, Park HJ, Han K, Kang SW, Ban JY, et al. Association between Secretoglobin family 3A member 2 (SCGB3A2) gene polymorphisms and asthma in a Korean Population. Med Sci Monit. 2017;23:1880–5.CrossRef
36.
go back to reference Tanaka H, Yanagisawa K, Shinjo K, Taguchi A, Maeno K, Tomida S, et al. Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res. 2007;67(13):6007–11.CrossRef Tanaka H, Yanagisawa K, Shinjo K, Taguchi A, Maeno K, Tomida S, et al. Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res. 2007;67(13):6007–11.CrossRef
37.
go back to reference Yamaguchi T, Hosono Y, Yanagisawa K, Takahashi T. NKX2-1/TTF-1: an enigmatic oncogene that functions as a double-edged sword for cancer cell survival and progression. Cancer Cell. 2013;23(6):718–23.CrossRef Yamaguchi T, Hosono Y, Yanagisawa K, Takahashi T. NKX2-1/TTF-1: an enigmatic oncogene that functions as a double-edged sword for cancer cell survival and progression. Cancer Cell. 2013;23(6):718–23.CrossRef
38.
go back to reference Stanfel MN, Moses KA, Schwartz RJ, Zimmer WE. Regulation of organ development by the NKX-homeodomain factors: an NKX code. Cell Mol Biol (Noisy-le-grand) 2005;Suppl 51:OL785–99. Stanfel MN, Moses KA, Schwartz RJ, Zimmer WE. Regulation of organ development by the NKX-homeodomain factors: an NKX code. Cell Mol Biol (Noisy-le-grand) 2005;Suppl 51:OL785–99.
39.
go back to reference Boggaram V. Thyroid transcription factor-1 (TTF-1/Nkx2.1/TITF1) gene regulation in the lung. Clin Sci (Lond). 2009;116(1):27–35.CrossRef Boggaram V. Thyroid transcription factor-1 (TTF-1/Nkx2.1/TITF1) gene regulation in the lung. Clin Sci (Lond). 2009;116(1):27–35.CrossRef
40.
go back to reference Minoo P, Hu L, Xing Y, Zhu NL, Chen H, Li M, et al. Physical and functional interactions between homeodomain NKX2.1 and winged helix/forkhead FOXA1 in lung epithelial cells. Mol Cell Biol. 2007;27(6):2155–65.CrossRef Minoo P, Hu L, Xing Y, Zhu NL, Chen H, Li M, et al. Physical and functional interactions between homeodomain NKX2.1 and winged helix/forkhead FOXA1 in lung epithelial cells. Mol Cell Biol. 2007;27(6):2155–65.CrossRef
41.
go back to reference Kurotani R, Tomita T, Yang Q, Carlson BA, Chen C, Kimura S. Role of secretoglobin 3A2 in lung development. Am J Respir Crit Care Med. 2008;178(4):389–98.CrossRef Kurotani R, Tomita T, Yang Q, Carlson BA, Chen C, Kimura S. Role of secretoglobin 3A2 in lung development. Am J Respir Crit Care Med. 2008;178(4):389–98.CrossRef
42.
go back to reference Zamecnik J, Kodet R. Value of thyroid transcription factor-1 and surfactant apoprotein A in the differential diagnosis of pulmonary carcinomas: a study of 109 cases. Virchows Arch. 2002;440(4):353–61.CrossRef Zamecnik J, Kodet R. Value of thyroid transcription factor-1 and surfactant apoprotein A in the differential diagnosis of pulmonary carcinomas: a study of 109 cases. Virchows Arch. 2002;440(4):353–61.CrossRef
43.
go back to reference Moldvay J, Jackel M, Bogos K, Soltész I, Agócs L, Kovács G, et al. The role of TTF-1 in differentiating primary and metastatic lung adenocarcinomas. Pathol Oncol Res. 2004;10(2):85–8.CrossRef Moldvay J, Jackel M, Bogos K, Soltész I, Agócs L, Kovács G, et al. The role of TTF-1 in differentiating primary and metastatic lung adenocarcinomas. Pathol Oncol Res. 2004;10(2):85–8.CrossRef
44.
go back to reference Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244–85.CrossRef Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244–85.CrossRef
45.
go back to reference Solis LM, Behrens C, Raso MG, Lin HY, Kadara H, Yuan P, et al. Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. Cancer. 2012;118(11):2889–99.CrossRef Solis LM, Behrens C, Raso MG, Lin HY, Kadara H, Yuan P, et al. Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. Cancer. 2012;118(11):2889–99.CrossRef
46.
go back to reference Tang X, Kadara H, Behrens C, Liu DD, Xiao Y, Rice D, et al. Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis. Clin Cancer Res. 2011;17(8):2434–43.CrossRef Tang X, Kadara H, Behrens C, Liu DD, Xiao Y, Rice D, et al. Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis and prognosis. Clin Cancer Res. 2011;17(8):2434–43.CrossRef
47.
go back to reference Anagnostou VK, Syrigos KN, Bepler G, Homer RJ, Rimm DL. Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol. 2009;27(2):271–8.CrossRef Anagnostou VK, Syrigos KN, Bepler G, Homer RJ, Rimm DL. Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol. 2009;27(2):271–8.CrossRef
48.
go back to reference Berghmans T, Paesmans M, Mascaux C, Martin B, Meert AP, Haller A, et al. Thyroid transcription factor 1–a new prognostic factor in lung cancer: a meta-analysis. Ann Oncol. 2006;17(11):1673–6.CrossRef Berghmans T, Paesmans M, Mascaux C, Martin B, Meert AP, Haller A, et al. Thyroid transcription factor 1–a new prognostic factor in lung cancer: a meta-analysis. Ann Oncol. 2006;17(11):1673–6.CrossRef
49.
go back to reference Winslow MM, Dayton TL, Verhaak RG, Kim-Kiselak C, Snyder EL, Feldser DM, et al. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature. 2011;473(7345):101–4.CrossRef Winslow MM, Dayton TL, Verhaak RG, Kim-Kiselak C, Snyder EL, Feldser DM, et al. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature. 2011;473(7345):101–4.CrossRef
50.
go back to reference Chiurillo MA. Role of the Wnt/β-catenin pathway in gastric cancer: An in-depth literature review. World J Exp Med. 2015;5(2):84–102.CrossRef Chiurillo MA. Role of the Wnt/β-catenin pathway in gastric cancer: An in-depth literature review. World J Exp Med. 2015;5(2):84–102.CrossRef
Metadata
Title
Transcriptome analysis reveals the essential role of NK2 homeobox 1/thyroid transcription factor 1 (NKX2-1/TTF-1) in gastric adenocarcinoma of fundic-gland type
Authors
Kazushi Fukagawa
Yu Takahashi
Nobutake Yamamichi
Natsuko Kageyama-Yahara
Yoshiki Sakaguchi
Miho Obata
Rina Cho
Nobuyuki Sakuma
Sayaka Nagao
Yuko Miura
Naoki Tamura
Daisuke Ohki
Hiroya Mizutani
Seiichi Yakabi
Chihiro Minatsuki
Keiko Niimi
Yosuke Tsuji
Mitsue Yamamichi
Narumi Shigi
Shuta Tomida
Hiroyuki Abe
Tetsuo Ushiku
Kazuhiko Koike
Mitsuhiro Fujishiro
Publication date
12-09-2022
Publisher
Springer Nature Singapore
Published in
Gastric Cancer / Issue 1/2023
Print ISSN: 1436-3291
Electronic ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-022-01334-5

Other articles of this Issue 1/2023

Gastric Cancer 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine